Vykat XR Post-Marketing Safety Reports Rise: Causality Undetermined in 7 Deaths

After patients with Prader-Willi syndrome finally gained access to a new drug for suppressing excessive appetite, a more difficult safety issue has now emerged in clinical practice. According to STAT, experts in the field have warned clinicians that, to date, 7 deaths and more than 100 serious adverse events have been reported among patients using Vykat XR, including pronounced swelling and respiratory or cardiac complications.

These figures do not mean that Vykat XR caused the deaths. Spontaneous adverse event reports may contain incomplete information or duplicate submissions, and they lack the complete number of treated patients needed to calculate incidence rates. Patients with Prader-Willi syndrome may also have comorbidities such as obesity, blood clots, and cardiopulmonary disease. Therefore, what can currently be established is that safety events have been reported, not that a causal relationship between the drug and the cases has been determined.

A case previously disclosed by Soleno Therapeutics to the U.S. Securities and Exchange Commission highlights the difficulty of interpretation. A 17-year-old patient died, with pulmonary embolism listed as the apparent cause of death. Both the treating physician and the company assessed the event as unrelated to Vykat XR, citing factors that included the patient’s pre-existing lymphedema, superficial thrombophlebitis, and obesity. The filing also emphasized that submitting information to the FDA Adverse Event Reporting System does not mean that the information has been medically verified, and causality cannot be inferred from a report alone.

However, some reported symptoms overlap with the drug’s known risks. The FDA-approved label warns that Vykat XR may cause edema and severe fluid overload, including pulmonary edema. In patients with insufficient cardiac reserve, the associated fluid retention may also precipitate congestive heart failure. In the controlled trial, edema occurred in 27% of the treatment group and 12% of the placebo group; the corresponding rates for hyperglycemia were 17% and 5%.

Pre-approval data provide another benchmark. In a long-term, open-label extension study involving 115 participants, FDA reviewers recorded that 16 people, or about 14%, experienced at least one serious adverse event. However, there were no deaths during the study, and no consistent pattern sufficient to constitute an unexpected safety signal was observed. The discrepancy between post-marketing reports and trial results may stem from a broader real-world population with more complex comorbidities, or it may reflect a drug-related risk; the available data are not yet sufficient to distinguish between the two.

The next key issue is not merely the cumulative number of cases, but whether the FDA and the company can obtain details such as medical records, timing of treatment, dosage, comorbidities, and changes after discontinuation to determine whether the events are concentrated among specific high-risk patients. For clinicians, monitoring fluid retention, respiratory symptoms, cardiac status, and blood glucose in accordance with the label, and reducing the dose or temporarily suspending treatment when necessary, will be central to clarifying the risk while maintaining access to treatment.